One clue comes from the Financial Times which moments ago reported that the Trump administration is "considering the bypassing normal US regulatory standards to fast-track an experimental coronavirus vaccine from the UK for use in America ahead of the presidential election."

The FT is referring to a covid vaccine trial being conducted by AstraZeneca, and whose fast-tracking "would involve the US Food and Drug Administration awarding 'emergency use authorisation' (EUA) in October to a vaccine being developed in a partnership between AstraZeneca and Oxford university, based on the results from a relatively small UK study if it is successful, the people said."